INSTRUCTIONS
for Use of the Veterinary Drug Letmoxiflox

1. General Information

1.1 The veterinary drug Letmoxiflox.

Pharmaceutical form: injectable solution.

International Nonproprietary Name: moxifloxacin.

1.2 The veterinary drug Letmoxiflox (hereinafter referred to as the drug) is a clear liquid ranging in color from colorless to yellow. Each 1.0 ml contains 100 mg of moxifloxacin as the active substance and the following excipients: propylene glycol, sodium hydroxide, distilled water.

1.3 The drug is available in 10, 50, and 100 ml glass vials sealed with rubber stoppers and aluminum caps.

1.4 Store the drug in the manufacturer's packaging in a dry, dark place at temperatures between +5°C and +25°C. Keep out of reach of children.

1.5 Shelf life is 2 (two) years from the date of manufacture if stored properly. Once the vial is opened, the drug must be used within 24 days, provided the remainder is stored at +3°C to +8°C. Do not use after the expiration date. Expired product should be disposed of in accordance with applicable regulations.

2. Pharmacological Properties

2.1 Moxifloxacin, the active ingredient in the drug, is a fourth-generation fluoroquinolone antibiotic with a broad spectrum of bactericidal activity. Its mechanism involves inhibition of bacterial enzymes, leading to disruption of DNA supercoiling and strand breakage, suppression of cell division, alteration of cytoplasm, and microbial death. It is effective against bacteria resistant to β-lactam and macrolide antibiotics.

2.2 The drug is active against most gram-positive and gram-negative aerobic bacteria, including: *Streptococcus spp., Staphylococcus spp., Enterococcus spp., Corynebacterium spp., Escherichia coli, Proteus spp., Enterobacter spp., Listeria monocytogenes, Actinobacillus pleuropneumoniae, Haemophilus parasuis, Salmonella spp., Citrobacter freundii, Campylobacter spp., Fusobacterium necrophorum, Clostridium spp.*, as well as chlamydia, mycoplasmas, and other pathogens sensitive to moxifloxacin.

2.3 After parenteral administration, moxifloxacin is rapidly absorbed at the injection site, reaching peak plasma concentration within 60–120 minutes. Highest concentrations are observed in the lungs, abdominal and pelvic organs, skeletal muscles, and skin. It is metabolized in the liver. The average half-life is approximately 12 hours.

3. Directions for Use

3.1 The drug is prescribed for pigs, cattle, and small ruminants to treat infectious diseases of the respiratory, digestive, and genitourinary systems, as well as skin, soft tissue, and other conditions caused by moxifloxacin-sensitive pathogens.

3.2 Administer intramuscularly to pigs, cattle, and small ruminants at a single dose of 1.0 ml per 10 kg of body weight. A repeat injection may be given after 48 hours. The maximum volume per injection site must not exceed 20.0 ml.

3.3 When used as directed, adverse effects or complications are generally not observed. A pain reaction at the injection site may occur. If an animal shows hypersensitivity to the drug, discontinue use and provide symptomatic treatment.

3.4 Do not use in animals with central nervous system disorders or severe cartilage development issues. Use during pregnancy is not recommended. Contraindicated in animals with hypersensitivity to the drug components.

3.5 Do not use simultaneously with amphenicols, macrolide antibiotics, tetracyclines, or steroidal anti-inflammatory drugs.

3.6 Slaughter of cattle for meat is allowed no earlier than 6 days after the last injection; for small ruminants and pigs, after 4 days. Meat from animals slaughtered before this period can only be used to feed carnivorous animals. Milk from treated dairy cows must not be used for human consumption during treatment and for 24 hours after the last administration. Such milk may be used for animal feed after heat treatment.

4. Precautionary Measures

4.1 Follow general personal hygiene and safety precautions when handling the drug.

4.2 Individuals with hypersensitivity to the components should avoid direct contact. Do not eat, drink, or smoke while handling the product. Wash hands with warm water and soap after use. Do not reuse empty containers for household purposes; dispose of them with regular waste.

4.3 In case of contact with skin or mucous membranes, rinse thoroughly with water. In case of allergic reaction or accidental ingestion, seek immediate medical attention and provide the product label or instructions.

5. Claims Procedure

5.1 In case of complications, stop using the drug and contact the manufacturer and the local State Veterinary Service. Veterinary specialists will investigate compliance with the instructions. If adverse effects are confirmed or visual defects are noted, samples will be collected for laboratory testing. A sample collection report will be issued, and the drug will be sent to the State Institution "Belarusian State Veterinary Center" (220005, Minsk, Krasnaya St. 19A) for compliance verification.

6. Manufacturer Information

6.1 Production Cooperative "Biogel", Republic of Belarus, 220035, Minsk, Timiryazev Street, 65, office 313, on behalf of the private manufacturing and trading unitary enterprise "Letyal", Republic of Belarus, 220005, Minsk, Engineering Street, 1-E.

The instruction was prepared by PC "Biogel", PPTUE "Letyal" (L.E. Yanushevskaya, A.N. Bezborodkin).